Sight Diagnostics
Tel Aviv
About Sight Diagnostics
Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science. Sight’s first product, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents. *Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $123.8M
- Funding stage: Late Stage Venture
- Last round: Series D (Aug 2020)
- Website: sightdx.com
- Phone: +972 26737370
Industries & Categories
Artificial Intelligence (AI), Computer Vision, Health Care, Health Diagnostics, Machine Learning
Social Profiles
Canonical: https://fsome.com/organization/sight-diagnostics-7113 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.